Large Volume Parenteral (LVP) Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2024-32
                     Global Large Volume 
Parenteral (LVP) Market 
Research and Forecast 
Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
Accord ing  to  t he  la tes t  r epor t  by  IMARC Group,  t i t l ed  " Large  Vo l ume Paren tera l  
(LVP)  Market :  G loba l  Indust ry  T rends ,  Share ,  S i ze ,  Growth ,  Oppor tun i ty  and  
Forecast  2024-2032 ,"  t he  g loba l  l a rge  vo lume pa ren t era l  (LVP)  marke t  s i ze  
reached  US$  9 .8  B i l l i on  i n  2023.
Report Factors Af fect ing  the  Growth  of  Large Volume Parentera l  (LVP)  Industry:
Increasing Prevalence of  Chronic  Diseases:
Highlight and The  la rge  vo lume paren te ra l  (LVP)  marke t  i s  w i tness ing  s ign i f i can t  g rowth  d r i ven  by  the  r i s ing  p reva lence  o f  ch ron ic  d iseases  wor ldw ide .  Chron ic  d iseases ,  such  
as  cancer ,  d iabe tes ,  ca rd iovascu la r  d iseases ,  and  au t o immune  d isorde rs ,  requ i re  
Description l ong - t e rm t rea tmen t  o f ten  i nvo l v i ng  i n t ravenous  admin i s t ra t ion  o f  med i ca t i ons  o r  
f l u ids .  
As  t he  g loba l  popu la t ion  ages  and l i f es t y l es  become inc reas ing l y  sedent ary ,  t he  
inc idence  o f  ch ron ic  d iseases  i s  on  the  r i se .  Th is  demograph ic  sh i f t  has  f ue led  
the  demand  fo r  LVP produc t s ,  wh ich  a re  essen t ia l  f o r  t he  de l i ver y  o f  l a rge  
vo lumes  o f  f l u i ds ,  e lec t ro ly tes ,  and  med ica t ions  t o  pa t ien ts .
Signi f icant  Technological  Advancements in Drug Del ivery Systems:
Technolog ica l  advancements  in  d rug de l ivery  sys tems are  p lay ing a  p ivo ta l  
ro le  in  d r iv ing  the g rowth  o f  the  la rge  vo lume paren tera l  (LVP)  marke t .  As 
pharmaceut ica l  compan ies  invest  in  research  and  deve lopment  to  enhance 
Report the  e f f i cacy ,  sa fe ty ,  and  conven ience  o f  d rug admin is t ra t ion ,  new and innovat ive  LVP products  a re  be ing in t roduced to  the  marke t .  One s ign i f i cant  
technolog ica l  advancement  con t r ibut ing  to  marke t  g rowth  i s  the deve lopment  
Highlight and of  advanced in fus ion pumps and  in fus ion sets .  
These  dev ices enab le  prec ise cont ro l  over  the admin is t ra t ion  ra te  and  
Description dosage o f  parente ra l  medica t ions and f lu ids ,  enhanc ing pat ien t  sa fe ty  and 
t rea tment  outcomes.  Fur thermore ,  the in tegra t ion  o f  smar t  techno logy  and 
connect iv i ty  featu res  in  in fus ion  pumps a l lows for  remote  moni to r ing and 
rea l - t ime da ta  t ransmiss ion ,  fac i l i ta t ing  more  e f f ic ien t  and  persona l ized  
pa t ien t  care .
Rising Demand for  Home Healthcare Services:
The r i s ing  demand fo r  home hea l thcare  serv ices  is  a  s ign i f ican t  fac to r  
dr i v ing the g rowth  o f  the  la rge vo lume paren tera l  (LVP)  market .
As hea l thcare  de l i ve ry  mode ls  evo lve  to  mee t  the  chang ing  needs  and  
p re fe rences  o f  pa t ien ts ,  t he re  i s  inc reas ing  emphas is  on  p rov id ing  med ica l  
ca re  in  the  comfor t  and  conven ience  o f  pa t ien ts '  homes.  Th is  sh i f t  toward  
home-based  ca re  is  d r i ven  by  va r ious  fac to rs ,  inc lud ing  demograph ic  changes,  
techno log ica l  advancements ,  and  e f fo r ts  to  con ta in  hea l thcare  cos ts .  One  key  
Report dr ive r  o f  t he  g row ing  demand fo r  home  hea l thca re  se rv i ces  is  t he  ag ing  
popu la t ion .  Wi th  a  la rger  p ropor t ion  o f  the  popu la t ion  en te r ing  o ld  age ,  t he re  
Highlight and i s  a  g rea te r  p reva lence  o f  ch ron ic  d iseases  and  age- re la ted  cond i t i ons  tha t  requ i re  ongo ing  med ica l  management .
Description Request  for  a  PDF sample  o f  th is  repor t :  
h t tps : / /www. imarcgroup .com/ la rge -vo lume-paren te ra l -marke t / reques tsamp le
Report Description
Global  Large Volume Parenteral  (LVP) Market Trends:
The r is ing  hea l thcare  expendi tu re  in  Nor th  Amer ica ,  d r i ven by  fac to rs  such  as  increas ing  hea l thcare  demand,  
technolog ica l  advancements ,  and the  p reva lence  o f  ch ron ic  d iseases,  i s  fue l ing  the  g rowth  o f  the  LVP market .  
Governments ,  pr i va te  hea l thcare  prov iders ,  and insurance  compan ies  are  a l locat ing substan t ia l  resources  to  
enhance  hea l thcare  in f ras t ruc tu re ,  expand access to  med ica l  se rv ices ,  and  improve pat ient  ou tcomes.  
As  a  resu l t ,  there  i s  growing inves tment  in  in t ravenous therap ies  and  parente ra l  nut r i t ion  so lu t ions,  d r i v ing  
the  demand fo r  LVP produc ts  ac ross var ious  hea l thcare  se t t ings ,  inc lud ing  hosp i ta ls ,  c l in ics ,  and  ambu la tory  
care  cen ters .
Looking forward ,  IMARC Group expects  the market  to  reach US$ 16.2  Bi l l ion  by  2032,  exhib i t ing  a  
growth  ra te  (CAGR)  of  5 .6% dur ing  2024-2032.
View Report  TOC,  F igures and Tables :  h t tps: / /www. imarcgroup.com/ large-vo lume-parentera l -market
Breakup by Type:
• Soft  Bag LVP
• Plast ic  Bott le LVP
• Glass Bott le LVP
Breakup by Volume:
Report • 100 ML -  250 ML
• 250 ML -  500 ML
Segmentation • 500 ML -  1000 ML
• 1000 ML -  2000 ML
• 2000 ML and More
Breakup by Application:
• Therapeutic  In ject ions
• Fluid Balance Injections
• Nutrit ious Injections
Breakup by End Users:
• Hospitals
• Clinics
• Others
Report 
Segmentation Breakup by Region:
• North America
• Asia-Pacifi c
• Europe
• Latin America
• Middle East and Afr ica
• Albert David Ltd.
• B. Braun Melsungen AG
• Baxter International  Inc.
Competitive • BML Parenteral Drugs
Landscape • Fresenius Kabi AG
• Grifo ls S.A
with Key 
• Otsuka Pharmaceutical  Co. Ltd
Players • Pharmaceutical Solutions Industry Ltd.
• Sichuan Kelun Pharmaceutical  Co. Ltd.
• Thermo Fisher Scient ifi c Inc.
How has the global large volume parenteral (LVP) 
market performed so far and how will it perform in the 
coming years?
What has been the impact of COVID-19 on the global 
large volume parenteral (LVP) market?
Key 
What are the key regional markets?
Questions 
Answered in What is the breakup of the market based on the type?
the Report What is the breakup of the market based on the 
volume?
What is the breakup of the market based on the 
application?
What is the breakup of the market based on the end 
users?
What are the various stages in the value chain of the 
industry?
What are the key driving factors and challenges in the 
industry?
What is the structure of the global large volume 
Key parenteral (LVP) market and who are the key players?
Questions What is the degree of competition in the industry?
Answered in 
the Report
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
        2 . 4 . 1     B o t t o m - U p  A p p r o a c h
Table of         2 . 4 . 2     T o p - D o w n  A p p r o a c h    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
    4 . 1     O v e r v i e w
Contents     4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  L a r g e  V o l u m e  P a r e n t e r a l  ( L V P )  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  T y p e
    6 . 1     S o f t  B a g  L V P
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  M a r k e t  F o r e c a s t
    6 . 2     P l a s t i c  B o t t l e  L V P
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
    6 . 3     G l a s s  B o t t l e  L V P
        6 . 3 . 1  M a r k e t  T r e n d s
        6 . 3 . 2  M a r k e t  F o r e c a s t
7    M a r k e t  B r e a k u p  b y  V o l u m e
       
 7 . 1     1 0 0  M L  -  2 5 0  M L
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
    7 . 2     2 5 0  M L  -  5 0 0  M L
        7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
    7 . 3     5 0 0  M L  -  1 0 0 0  M L
        7 . 3 . 1  M a r k e t  T r e n d s
        7 . 3 . 2  M a r k e t  F o r e c a s t
    7 . 4     1 0 0 0  M L  -  2 0 0 0  M L
        7 . 4 . 1  M a r k e t  T r e n d s
        7 . 4 . 2  M a r k e t  F o r e c a s t
Table of     7 . 5     2 0 0 0  M L  a n d  M o r e
        7 . 5 . 1  M a r k e t  T r e n d s
        7 . 5 . 2  M a r k e t  F o r e c a s t
Contents 8    M a r k e t  B r e a k u p  b y  A p p l i c a t i o n    8 . 1     T h e r a p e u t i c  I n j e c t i o n s
        8 . 1 . 1  M a r k e t  T r e n d s
        8 . 1 . 2  M a r k e t  F o r e c a s t
    8 . 2     F l u i d  B a l a n c e  I n j e c t i o n s
        8 . 2 . 1  M a r k e t  T r e n d s
        8 . 2 . 2  M a r k e t  F o r e c a s t
    8 . 3     N u t r i t i o u s  I n j e c t i o n s
        8 . 3 . 1  M a r k e t  T r e n d s
        8 . 3 . 2  M a r k e t  F o r e c a s t
9    M a r k e t  B r e a k u p  b y  E n d  U s e r s
    9 . 1     H o s p i t a l s
        9 . 1 . 1  M a r k e t  T r e n d s
        9 . 1 . 2  M a r k e t  F o r e c a s t
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht t ps : / /w ww. i ma rc gro up . c o m / l a rge -v o l um e -pa ren t e ra l -m a rke t /
t o c
Disclaimer
© 2023  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
TELEPHONE: +1-631-791-1145 
E-MAIL: [email protected]